Arash Navran is an expert in Radiotherapy at Antoni van Leeuwenhoek Hospital (Netherlands). Arash Navran has authored 55 publications, the most recent in 2025. SLR score: 105 (community average: 125). How the SLR is computed.

LeadR Profile

Arash Navran Antoni van Leeuwenhoek Hospital Netherlands
105 ScienceLeadR Reputation 105
Network Map

Radiotherapy

Subspecialties: Oncology - Otolaryngology - Nuclear Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2009 - 2026

Source: PubMed

Antoni van Leeuwenhoek Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 55

Citations

Citations: 817 1st author: 6 Last author: 0 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
SPECT/CT-based sentinel node procedure to guide unilateral elective nodal irradiation in patients with head and neck cancer: technical feasibility and sentinel node mapping outcomes.
PMID 41206395 — drainage, single photon emission computed tomography computed tomography, neoplasms, tomography, emission-computed, single-photon, head and neck neoplasms
Eur Arch Otorhinolaryngol20250
Brachytherapy (interventional radiotherapy) for lip carcinoma: excellent local control, low toxicity profile, and high patient satisfaction - The Dutch experience from four brachytherapy-dedicated head and neck cancer centers.
PMID 41187793 — radiotherapy, brachytherapy, neoplasms, head and neck neoplasms, patient satisfaction, lip
Radiother Oncol20250
[ 18F]FDG-PET/CT's change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial.
PMID 41145919 — cells, carcinoma, squamous cell, immunotherapy, fluorodeoxyglucose f18, nuclear medicine, therapeutics, non-responder, cutaneous squamous cell carcinoma
Eur J Nucl Med Mol Imaging20250
Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.
PMID 41062829 — cells, quality of life, molecular biology, tomography, carcinoma, squamous cell, nivolumab, ipilimumab, cutaneous squamous cell carcinoma
Nat Med Top journal20251
Postoperative complications following salvage neck dissection after (chemo)radiotherapy for head and neck squamous cell carcinoma: which patients are at high risk?
PMID 40316947 — radiotherapy, cells, incidence, neck dissection, carcinoma, squamous cell, squamous cell carcinoma of head and neck, dissection, postoperative complications
BMC Cancer20250

LeadR Networks

Main global connection map